Meeting
2018 ASCO Annual Meeting
Can duration of response be used as a surrogate endpoint for overall survival in advanced non-small cell lung cancer?
Authors
Boris M Pfeiffer
Merck KGaA, Darmstadt, Germany
Boris M Pfeiffer , Margarita Kulakova , Mahmoud Hashim , Bart Heeg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9082)
DOI
10.1200/JCO.2018.36.15_suppl.9082
Abstract #
9082
Poster Bd #
405
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Amivantamab and lazertinib in treatment-naïve EGFR-mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.
First Author: Se-Hoon Lee
Poster
2017 ASCO Annual Meeting
Objective response rate and progression-free survival as surrogate endpoints for overall survival and the impact of crossover and unbalanced post-progression treatments: A systematic review and meta-analysis in first-line therapy of advanced non-small cell lung cancer.
First Author: Boris Pfeiffer
Poster
2017 ASCO Annual Meeting
Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study.
First Author: David Planchard
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Camrelizumab plus apatinib after progression on immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma (CAP 02 Re-challenge): A single-arm multicenter, phase II trial.
First Author: Xiangrui Meng